Clear cell papillary renal cell carcinoma is a distinct variant of renal cell carcinoma that shares some overlapping histological and immunohistochemical features of clear cell renal cell carcinoma and papillary renal cell carcinoma. Although the clear cell papillary renal cell carcinoma immunohistochemical profile is well described, clear cell papillary renal cell carcinoma mRNA expression has not been well characterized. We investigated the clear cell papillary renal cell carcinoma gene expression profile using previously identified candidate genes. We selected 17 clear cell papillary renal cell carcinoma, 15 clear cell renal cell carcinoma, and 13 papillary renal cell carcinoma cases for molecular analysis following histological review. cDNA from formalin-fixed paraffinembedded tissue was prepared. Quantitative real-time PCR targeting alpha-methylacyl coenzyme-A racemase (AMACR), BMP and activin membrane-bound inhibitor homolog (BAMBI), carbonic anhydrase IX (CA9), ceruloplasmin (CP), nicotinamide N-methyltransferase (NNMT), schwannomin-interacting protein 1 (SCHIP1), solute carrier family 34 (sodium phosphate) member 2 (SLC34A2), and vimentin (VIM) was performed. Gene expression data were normalized relative to 28S ribosomal RNA. Clear cell papillary renal cell carcinoma expressed all eight genes at variable levels. Compared with papillary renal cell carcinoma, clear cell papillary renal cell carcinoma expressed more CA9, CP, NNMT, and VIM, less AMACR, BAMBI, and SLC34A2, and similar levels of SCHIP1. Compared with clear cell renal cell carcinoma, clear cell papillary renal cell carcinoma expressed slightly less NNMT, but similar levels of the other seven genes. Although clear cell papillary renal cell carcinoma exhibits a unique molecular signature, it expresses several genes at comparable levels to clear cell renal cell carcinoma relative to papillary renal cell carcinoma. Understanding the molecular pathogenesis of clear cell papillary renal cell carcinoma will have a key role in future sub-classifications of this unique tumor.
Clear cell papillary renal cell carcinoma is a morphologically and immunohistochemically distinct renal epithelial neoplasm originally described as a 'clear cell papillary renal cell carcinoma of endstage kidneys'. 1 Since its initial description, it is apparent that although clear cell papillary renal cell carcinoma has a propensity to arise in the setting of end-stage kidney disease, these tumors can occur de novo in normal kidneys. Histologically, clear cell papillary renal cell carcinoma is characterized by papillary infoldings composed almost entirely of cells with clear cytoplasm and polarized low-grade nuclei. Immunohistochemically, clear cell papillary renal cell carcinoma expresses cytokeratin 7 and carbonic anhydrase IX (CA9) but does not express alpha methyl-coenzyme-A racemase (AMACR), CD10, or transcription factor E3 (TFE3). 2 Clear cell papillary renal cell carcinoma does not harbor the chromosome 3p deletions seen in clear cell renal cell carcinoma or demonstrate trisomies 7 and 17, or loss of Y that is characteristic of papillary renal cell carcinoma. 3 Clearly, clear cell papillary renal cell carcinoma is a distinct tumor that shares some morphological, immunohistochemical, and molecular features of both clear cell renal cell carcinoma and papillary renal cell carcinoma, but few studies have examined the molecular gene expression profile of these neoplasms. Although clear cell papillary renal cell carcinoma may have overlapping morphological features with clear cell renal cell carcinoma and papillary renal cell carcinoma (especially those with clear cell features) in areas, clear cell papillary renal cell carcinoma and papillary renal cell carcinoma are more aggressive tumors. Herein, using real-time (RT)-PCR, we targeted eight previously identified candidate genes (Table 1) to assess their expression levels in clear cell papillary renal cell carcinoma, clear cell renal cell carcinoma, and papillary renal cell carcinoma. We selected a panel of four candidate clear cell renal cell carcinoma markers and four papillary renal cell carcinoma markers, which had been identified in previous expression-profiling studies from our group. These markers were chosen to study whether the novel subtype clear cell papillary renal cell carcinoma was distinct from or similar to clear cell renal cell carcinoma or papillary renal cell carcinoma in terms of gene expression.
Materials and methods

Case Selection and Analysis
Seventeen cases of clear cell papillary renal cell carcinoma, 15 cases of clear cell renal cell carcinoma, and 13 cases of papillary renal cell carcinoma were selected for analysis. All cases were re-reviewed by a urological pathologist. The diagnosis of clear cell papillary renal cell carcinoma was based on classic morphological features and corresponding immunohistochemical profile (positive cytokeratin 7 expression and negative CD10, P504S/AMACR and TFE3 expression). Tumor grading and staging was based on the standard Fuhrman nuclear-grading system and the American Joint Committee on Cancer, 7th edition tumor-node-metastasis staging system, respectively. 4, 5 This study was completed following the guidelines of and with approval from the institutional review board of our institution.
Quantitative RT-PCR
Quantitative RT-PCR experiments were performed in duplicate on total RNA isolated from formalinfixed paraffin-embedded tissue from each specimen. Unstained histological sections were deparaffinized with ethanol and xylene. The tumor cells were microdissected with a sterile scalpel. Tissue was digested in buffer containing proteinase K at 60 1C overnight, and total RNA was isolated by phenol chloroform extraction and subjected to DNase treatment. RNA quality and quantity were assessed with Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Up to 3 mg of RNA was used for first-strand cDNA synthesis with Superscript III (Invitrogen/ Life Technologies, Grand Island, NY, USA). PCR was carried out with sybrogreen master mix (Applied Biosystems/Life Technologies) in the 96-well format using ABI PRISM 7500 Fast RT-PCR system. PCR runs were analyzed by using Relative Quantification Manager (Applied Biosystems) software. Relative mRNA expression levels of eight genes (AMACR, BAMBI, CA9, CP, NNMT, SCHIP1, SLC34A2, and VIM, see Table 1) were assessed. These genes were selected from previous data generated by our laboratory as markers of clear cell renal cell carcinoma and papillary renal cell carcinoma. 6 
Data Analysis
Gene expression data were normalized relative to the geometric mean of the 28S ribosomal RNA housekeeping gene. mRNA extracted from normal kidney was used as a reference standard. For each tumor, the relative mean C t of each gene was calculated as follows: (value well 1 þ value well 2)/2. The tumor DC t was calculated as follows: gene tested relative mean C t À 28SRNA relative mean C t . The DDC t was Table 2 .
Quantitative RT-PCR, Data Analysis and Statistics
The differential mRNA expression ( À DDCt) of the four papillary renal cell carcinoma genes (AMACR, BAMBI, SCHIP1, and SLC34A2) and the four clear cell renal cell carcinoma genes (CA9, NNMT, CP, and VIM) in each of the 45 individual renal cell carcinomas is shown in Figures 2a and b , respectively. The individual À DDCt values for the papillary renal cell carcinoma genes and the clear cell renal cell carcinoma genes were normalized using a log2 transformation (2 ( À DDCt) , Figures 3 and 4 , respectively), and the results were averaged to give an overall mean-normalized mRNA expression value for the entire cohort of clear cell papillary renal cell carcinoma, papillary renal cell carcinoma and clear cell renal cell carcinoma ( Figure 5 ). The data points were statistically analyzed using the Wilcoxon rank-sum test ( Figure 2 ) or Student's t-test ( Figure 5 ). When comparing clear cell papillary renal cell carcinoma with papillary renal cell carcinoma, clear cell papillary renal cell carcinoma were characterized by overexpression of CA9, ceruloplasmin (CP), and vimentin (VIM; P ¼ 0.001, 0.003, and o0.001, respectively, by Wilcoxon rank-sum test; P ¼ 0.56, 0.031, and 0.020, respectively, by Student's t-test) and relative overexpression of CP and nicotinamide N-methyltransferase (NNMT) when examined individually (P ¼ 0.001 and o0.001, respectively, by Wilcoxon rank-sum test). The transformed and averaged values for CP and NNMT approached statistical significance (P ¼ 0.056 and 0.068, respectively, by Student's t-test). Clear cell papillary renal cell carcinoma showed relative underexpression of AMACR, BAMBI, and SLC34A2 (Po0.001, o0.001, and ¼ 0.014, respectively, by Wilcoxon rank-sum test and P ¼ 0.005, o0.001, and ¼ 0.001, respectively, by Student's t-test). Clear cell papillary renal cell carcinoma and papillary renal cell carcinoma expressed comparable levels of schwannomin-interacting protein 1 (SCHIP1; approached statistical significance by Wilcoxon rank-sum test but not statistically significant by Student's t-test). The statistical analyses of the genes expressed in clear cell papillary renal cell carcinoma vs papillary renal cell carcinoma are summarized in Table 3 .
When comparing clear cell papillary renal cell carcinoma with clear cell renal cell carcinoma, clear cell papillary renal cell carcinoma expressed slightly lower levels of NNMT (approached statistical significance by Wilcoxon rank-sum test (P ¼ 0.041) but not significant by Student's t-test). No statistically significant differences (by Wilcoxon rank-sum test or Student's t-test) in AMACR, BAMBI, SCHIP1, SLC34A2, CA9, CP, or VIM expression were seen between clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma. The statistical analyses of the genes expressed in clear cell papillary renal cell carcinoma vs clear cell renal cell carcinoma are summarized in Table 3 .
When comparing clear cell renal cell carcinoma with papillary renal cell carcinoma, clear cell renal cell carcinoma expressed relatively higher amounts of CA9, CP, NNMT, and VIM (P ¼ 0.002, 0.037, o0.001, and o0.001, respectively, by Wilcoxon rank-sum test; P ¼ 0.023, 0.007, o0.001, and 0.009, respectively, by Student's t-test). Papillary renal cell carcinoma expressed relatively higher amounts of AMACR (P ¼ 0.001 by Wilcoxon rank-sum test and P ¼ 0.036 by Student's t-test) and BAMBI (BMP and activin membrane-bound inhibitor homolog; Po0.001 by Wilcoxon rank-sum test and Student's t-test). Papillary renal cell carcinoma demonstrated relative overexpression of SLC34A2 (P ¼ 0.033 by Wilcoxon rank-sum test), and the relative overexpression approached statistical significance when the values were transformed and averaged (P ¼ 0.066 by Student's t-test). Papillary renal cell carcinoma expressed slightly higher levels of SCHIP1 compared with clear cell renal cell carcinoma (approached statistical significance by Wilcoxon rank-sum test (P ¼ 0.065) but not significant by Student's t-test). These results are consistent with our previous work. 6 Statistical analysis of the genes expressed in papillary renal cell carcinoma vs clear cell renal cell carcinoma is summarized in Table 4 .
Discussion
Clear cell papillary renal cell carcinoma is a morphologically and immunohistochemically unique subset of renal cell carcinoma that do not harbor consistent chromosomal imbalances or VHL mutations according to the few molecular studies reported in the literature. 7, 8 To our knowledge, no studies have examined the mRNA expression of distinct papillary renal cell carcinoma or clear cell renal cell carcinoma genes in clear cell papillary renal cell carcinoma. Our data show that clear cell papillary renal cell carcinoma expresses abundant CA9, CP, NNMT, and VIM compared with papillary renal cell carcinoma, and somewhat similar but not Previous studies have shown that clear cell renal cell carcinoma shows abundant expression of VIM, a diversely expressed intermediate filament that has a role in cell adhesion, migration, survival, and epithelial-to-mesenchymal transition. 9 A recent report suggests that VIM overexpression functions as a renal cell carcinoma oncogene and is regulated by miRNA-138. 10 Furthermore, clear cell papillary renal cell carcinoma demonstrates increased VIM expression by immunohistochemistry, a feature that can be useful in the pathological diagnosis of these tumors. 11 VIM is dysregulated in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma, but the contribution of VIM to the pathogenesis of clear cell papillary renal cell carcinoma is unclear and merits further investigation.
Clear cell papillary renal cell carcinoma expressed low levels of AMACR, BAMBI, and SLC34A2. The low AMACR expression is consistent with the absence of AMACR immunohistochemical staining described in this tumor. 3, 12, 13 AMACR, BAMBI, and SLC34A2 are genes that are expressed at higher levels in papillary renal cell carcinoma, suggesting that clear cell papillary renal cell carcinoma is molecularly distinct from papillary renal cell carcinoma. However, SCHIP1 was expressed at a similar level between the two tumor types; therefore, some molecular overlap does exist. Future studies are needed to characterize additional papillary renal cell carcinoma genes that are differentially expressed compared with clear cell papillary renal cell carcinoma in order to better characterize the distinct molecular phenotype of clear cell papillary renal cell carcinoma compared with papillary renal cell carcinoma. Clear cell papillary renal cell carcinoma also expressed high levels of CP and CA9 similar to the levels seen in clear cell renal cell carcinoma. CP is an acute-phase reactant protein that is expressed in many inflammatory situations, and serum CP protein levels are elevated in patients with renal cell carcinoma. 6 CA9 is a hypoxia-inducible protein overexpressed in clear cell renal cell carcinoma secondary to VHL dysregulation, but Rohan et al. 8 showed that CA9 upregulation in clear cell papillary renal cell carcinoma occurs via a VHL-independent mechanism. 8, 14 These observations suggest that although clear cell papillary renal cell carcinoma overexpresses CA9, the pathway for its overexpression is likely different than that of clear cell renal cell carcinoma. This supports the hypothesis that although clear cell papillary renal cell carcinoma share some molecular features with clear cell renal cell carcinoma, unique molecular pathway alterations exist.
Clear cell papillary renal cell carcinoma are typically described as low-grade malignancies. 7 In our study, clear cell papillary renal cell carcinoma tended to be smaller, multifocal, and of lower pathological stage and grade, which was similar to the clinicopathological features seen in papillary renal cell carcinoma (Table 2 ). These clinicopathological features were not shared with clear cell renal cell carcinoma; clear cell renal cell carcinoma were larger, all unifocal, and most were in pathological stage T3 or greater (Table 2) . However, the gene expression profile of the eight tested genes in clear cell papillary renal cell carcinoma was more similar to clear cell renal cell carcinoma (seven of the eight genes showed similar expression profiles) and not papillary renal cell carcinoma (only SCHIP1 showed similar expression). The fact that clear cell papillary renal cell carcinoma exhibit clinicopathological similarities to papillary renal cell carcinoma, but exhibit a gene expression profile that closely resembles clear cell renal cell carcinoma, underscores the need for additional translational studies The nonparametric Wilcoxon rank-sum test is much less sensitive to outliers than the parametric Student's t-test, but the Student's t-test is a more conventional method to assess log2-transformed expression data. There are several potential outlying data points that may have skewed the Student's t-test results (Figures 3  and 4) . However, we do not believe that this discordance in statistical significance between the Wilcoxon rank-sum test and Student's t-test compromises our primary conclusions, but rather reinforces the need to validate these data with additional tumor samples. Statistical discordance was also seen with SCHIP1 (approached significance by Wilcoxon rank-sum test but not Student's t-test) and SLC34A2 mRNA (significant by Wilcoxon rank-sum test but approached significance by Student's t-test) when comparing clear cell renal cell carcinoma with papillary renal cell carcinoma (Figures 3 and 4 , and Table 4 ). However, previous studies with more samples clearly validated this association, further supporting the conclusion that a larger n is needed to mitigate the influence of outlying data points. 6 In conclusion, our study demonstrates that clear cell papillary renal cell carcinoma exhibits a unique molecular signature when compared with clear cell renal cell carcinoma and papillary renal cell carcinoma, and although this signature is distinct, it expresses several genes at comparable levels to clear cell renal cell carcinoma relative to papillary renal cell carcinoma. Understanding the molecular pathogenesis of clear cell papillary renal cell carcinoma will have a key role in future subclassifications of this unique tumor.
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